A prospective trial needs to be done in order to create a safe and responsible environment in which to offer patients the watch-and-wait option for rectal cancer.
Thomas J. Stahl, MD, FACS, FASCRS
Advertisement
Articles by Thomas J. Stahl, MD, FACS, FASCRS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Lenvatinib/Pembrolizumab Shows Promise After IO Progression in GYN Cancers
2
Lymphoma's Revolution: Evens & Rhodes on CLL, CAR-T, and NJ Care
3
Making Nuanced Decisions on CAR-T and Bispecifics in Multiple Myeloma
4
How Have Bispecific Antibodies Evolved in Multiple Myeloma?
5